Currently, a number of vaccines or antiviral drugs for COVID-19 have been approved or are under development, and patients are currently treated symptomatically. For both vaccines and therapeutics, the antibodies produced are tested for their functional efficacy to neutralize the target virus. 

The cell-based assays market is projected to reach USD 22.0 billion by 2025, at a CAGR of 8.1% during the forecast period. The increasing preference for cell-based assays, the increase in the number of drug discovery activities, and surging research funding are all driving this industry forward. However, reagent restrictions and high instrument costs are two main challenges limiting the market's growth.  

Cell-based assays are employed to shorten the time and increase the throughput needed for these assays. This has significantly increased the demand for cell-based assays to provide an early indication of the toxicity characteristics of the drug candidates. 

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=119917269 

Cell-based assays are key components in the drug development process. Cell-based assays have several advantages over in vitro biochemical assays. They offer consistent tissue-specific responses in a biologically relevant microenvironment as opposed to biochemical assays.  

The growth of the reagents market is restricted by a different factor—product end-user licenses restrict the use of reagent kits only to specified assays. Due to this, even though better and superior reagents are available in the market, customers are restricted to using only those reagents specified in the license agreement. 

The conventional methods of toxicity and drug safety assessment (involving animal testing) are expensive, time-consuming, and offer low-throughput. In this regard, modern cell-based assays merge the advantages of cell cultures and animal models to allow researchers to identify problems with lead compounds in early screening, ensuring greater efficiency in the drug discovery and development process. 

Some of the prominent players in the cell-based assays market are Thermo Fisher Scientific, Inc. (US), Danaher Corporation (Beckman Coulter, Inc.) (US), Becton, Dickinson and Company (US), GE Healthcare (US), Merck KGaA (Germany), Lonza Group (Switzerland), PerkinElmer, Inc. (US) .